Van Campen Liem assisted Prilenia Therapeutics

Van Campen Liem assisted Prilenia Therapeutics in its $62.5M Series A Funding Round. The clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders will use the raised funding to launch the company’s two late-stage clinical trials of pridopidine in Huntington Disease (HD) and Amyotrophic Lateral Sclerosis (ALS).

The Series A round was led by Forbion, and accompanied by Morningside Venture Investments, Sectoral Asset Management, Talisman Capital Ventures and Genworks 2. The Series A financing brings the total capital investment in Prilenia Therapeutics since its foundation in September 2018 to $84.5M. As part of this Series A round, a new Dutch company, Prilenia Therapeutics B.V. has been formed. The new company will hold the Israeli subsidiary company Prilenia Neurotherapeutics Ltd.

The Van Campen Liem team consisted of Edwin Liem (partner), Martina Priekaar (senior-associate) and Anna Zhu (associate).

More information can be found here:

Edwin LiemMartina PriekaarAnna Zhu

Edwin Liem, Martina Priekaar and Anna Zhu.